Key result
Late symptomatic anthracycline cardiomyopathy presented 6-19 years post-therapy, with 14 of 15 patients developing conduction abnormalities or dysrhythmias and 3 dying suddenly.
Population
15 patients with late symptomatic anthracycline cardiomyopathy, representing a subset of 300 patients…
Design
Case_series
Follow-up
1-9 (median 3) years after late decompensation
Authors
Loading...
May support prolonged cardiac surveillance after anthracycline therapy; leaves open optimal protocols and duration.
Case Report (n=15)
Late symptomatic anthracycline cardiomyopathy can present with severe heart failure and life-threatening dysrhythmias more than a decade after treatment, highlighting the need for long-term surveillance.
Steinherz et al. (1995) conducted a case report in Late symptomatic anthracycline cardiomyopathy (n=15). Anthracycline therapy (daunorubicin and/or doxorubicin) was evaluated on Clinical course, cardiac function, and dysrhythmias. Late symptomatic anthracycline cardiomyopathy presented 6-19 years post-therapy, with 14 of 15 patients developing conduction abnormalities or dysrhythmias and 3 dying suddenly.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: